Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCUDDO: One vs Two Doses of HPV Vaccine
NCT03180034Phase 4Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2017
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine and human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection (4 arms), sponsored by National Cancer Institute. Primary endpoints: Occurrence of at least one incident persistent human papillomavirus (HPV)-16 and/or HPV-18 cervical infections, Incident persistent HPV-16 and/or HPV-18 cervical infections and 1 more. Started Nov 2017; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccinehuman papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03180034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180034.